Romidepsin (FK228, Depsipeptide)

For research use only. Not for use in humans.

目录号:S3020 别名: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

CAS No. 128517-07-7

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。Romidepsin (FK228/depsipeptide) 在神经母细胞瘤肿瘤细胞中可控制生长并诱导凋亡。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 13415.22 现货
RMB 1285.83 现货
RMB 3910.79 现货
RMB 5710.89 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Romidepsin (FK228, Depsipeptide)发表文献120篇:

产品安全说明书

HDAC抑制剂选择性比较

生物活性

产品描述 Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176)是一种有效的HDAC1HDAC2抑制剂,无细胞试验中IC50分别为36 nM和47 nM。Romidepsin (FK228/depsipeptide) 在神经母细胞瘤肿瘤细胞中可控制生长并诱导凋亡。
特性 Romidepsin对I型HDAC的抑制作用明显强于对II型HDAC的抑制。
靶点
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
体外研究

Romidepsin抑制NSCLC细胞系生长,IC50范围从1.3 ng/mL到4.9 ng/mL。 Romidepsin可以降低Erlotinib对NSCLC细胞系的IC50值, 增加NSCLC细胞系对Erlotinib的敏感性[1]。Romidepsin处理72小时可以抑制6/6 人 NB 肿瘤细胞系的生长,而 NIH3T3细胞系并不受影响。 Romidepsin对于单拷贝或N-myc 多拷贝的NB细胞系以及含有正常或突变的p53 和含有Alk突变体的细胞系都有选择性的细胞毒性,这种毒性具有剂量依赖的特性。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 M1fseGNmdGxiVnnhZoltcXS7IFHzd4F6 M3LMUFIvPS1zNTDuUS=> NGHlXGE4OiCq NHX3dFNqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi Mn2zNlU4QTB7MEe=
U2932  MUPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2SzS|IvPS1zNTDuUS=> MlHpO|IhcA>? MnPPbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NF;EUJYzPTd7MEmwOy=>
OCI-LY7 M{nJVWNmdGxiVnnhZoltcXS7IFHzd4F6 M1jUfVIvPS1zNTDuUS=> NGr0TlM4OiCq MmfGbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? M3vseFI2PzlyOUC3
Farage M{HGd2NmdGxiVnnhZoltcXS7IFHzd4F6 MWKyMlUuOTVibl2= Mne2O|IhcA>? NFO2dJpqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MoTRNlU4QTB7MEe=
LY7/EBV MnvCR4VtdCCYaXHibYxqfHliQYPzZZk> MYWyMlUuOTVibl2= M{T1O|czKGh? M{PDO4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NXrWZldROjV5OUC5NFc>
U2932/EBV NVrh[mN1S2WubDDWbYFjcWyrdImgRZN{[Xl? MmrENk42NTF3IH7N MVW3NkBp NXrmPYxTcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MYqyOVc6ODlyNx?=
HCT116 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XQdVUuPTByMDDuUS=> M1W5SlI1KGh? M2nqcmROW09? NFvjd3lqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> M2GyVVI2PDl{NUG1
ACH-2 NVHVdWZQTnWwY4Tpc44hSXO|YYm= NH;TcI8yNTlibl2= MmDSNlQhcA>? MV\pcoR2[2W|IFjJWk0yKEWwdjDlfJBz\XO|aX;u NFPmTpUzPTF2OUS2Oy=>
MCF-10A NHf3OnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwMUhCtVAvODFibl2= NXfOT2FYOjR7NUS4OVY>
MCF-7 MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwMUFCtVAvOjBibl2= M4i1bVI1QTV2OEW2
SK-BR-3 M2HFTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rVTGlEPTB;MT6wNOKyOC5|NTDuUS=> MljNNlQ6PTR6NU[=
MDA-MB-231 MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlewTWM2OD1yLk[4xtExNjF2IH7N M2frTlI1QTV2OEW2
PC3 NXf6fm9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojuTWM2OD1zLk[1xtExNjN3IH7N MlzXNlQ6PTR6NU[=
HCT116 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XRXWlEPTB;MT6wNOKyOC5yMDDuUS=> MoKzNlQ6PTR6NU[=
HCT116-p21-/- NIDPNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL5cY9zUUN3ME2xMlI3yrFyLkO3JI5O Mmq4NlQ6PTR6NU[=
S1 M2DjWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFroe3lKSzVyPUeuOlfDuTBwMkmgcm0> M{fmTVI1QTV2OEW2
SW620 MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwOURCtVAvOjlibl2= M161SlI1QTV2OEW2
LOX-IMVI NGG5Z4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXuTWM2OD1yLki3xtExNjB|IH7N M4nqNVI1QTV2OEW2
UACC-62 NHrmToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInrUldKSzVyPUCuOVbDuTBwMU[gcm0> NIfNfJkzPDl3NEi1Oi=>
MDA-MB-435 NVf5PHZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU[xco5pUUN3ME2wMlkxyrFyLkC2JI5O NF35SoYzPDl3NEi1Oi=>
SF-295 M1fIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTVTWM2OD1yLki4xtExNjF3IH7N NEDEfWwzPDl3NEi1Oi=>
A549 NIe5SVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwMkdCtVAvOjRibl2= MnjONlQ6PTR6NU[=
H460 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJwNUlCtVAvQDBibl2= NWO3XZZJOjR7NUS4OVY>
EKVX MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFwM{RCtVAvOzRibl2= M13TU|I1QTV2OEW2
H146 MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj4TI5pUUN3ME2wMlIzyrFyLkC3JI5O NWqxO2xwOjR7NUS4OVY>
H526 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HjOGlEPTB;MD6xOeKyOC5yMzDuUS=> NVzYbYR2OjR7NUS4OVY>
HuT-78 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37IVmlEPTB;MT63N:KyOC52NDDuUS=> NFLtXWUzPDl3NEi1Oi=>
HA NFjNOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\kNE43OjVvMUDuUS=> MYe0PEBp Mmj5bY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> NELEXm0zPDd5MUWxNC=>
MS-275 Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnpNE43OjVvMUDuUS=> M33WTVQ5KGh? Mnn6bY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> NGXvbokzPDd5MUWxNC=>
CD4 T NUjsV2pYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jsdFQ5KGh? MnTJSWM2OD12LkZCtVEvOCCwTR?= MW[yOFczOjR3NB?=
CD4 T MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPQN|B2PDhiaB?= NVTtW4lSS0N3ME2xNFfDuTF{NjDuUS=> MljDNlQ4OjJ2NUS=
CD4+ T MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknDSWM2OD1|IH7N M4fmbFI1PDl3MUC1
A549 NUf1TYZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVmxNQKBmzFyMNMgcm0> M2TUT|I1NzN4L{S4JIg> MkGybY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NITYVVIzPDR6NUe5PS=>
JJN3 M3uzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn3W4d2OjRxNEigbC=> Mo\aSWM2ODxz4pEJcm08KDR64pEJbC=> M2DTSlI1ODNyMUWw
OPM-2 M{XmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrJNJgzPC92ODDo MoPESWM2OHN;MfMAjY5OQyB2OPMAjYg> NETGNZczPDB|MEG1NC=>
RPMI-8226 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPnU2YzPC92ODDo M17URWVEPTC|PUGuPQKBkW6POzC0PQKBkWh? MnHQNlQxOzBzNUC=
U266 M3zvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHRRZgzPC92ODDo NUToOGkyTUN3MIO9NVDjiImwTUugOFjjiImq NFHhWVUzPDB|MEG1NC=>
CA46 MnjsRZBweHSxc3nzJGF{e2G7 M2n1[|YhcA>? NH\zWXlqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NFzlSngzOzl4NkG2OC=>
DG75 M3HY[2Fxd3C2b4Ppd{BCe3OjeR?= NFjRNng3KGh? NVXDfFBjcW6mdXPld{BvdyCjcH;weI9{cXN? M2fkTFI{QTZ4MU[0
Ramos NGnZWYlCeG:ydH;zbZMhSXO|YYm= MnLOOkBp MonvbY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nz NYPqcIF[OjN7Nk[xOlQ>
ST486 MYnBdI9xfG:|aYOgRZN{[Xl? NHzZNXU3KGh? NE\rTXdqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> NEX5emczOzl4NkG2OC=>
HuT78 MnL0RZBweHSxc3nzJGF{e2G7 NWDLUHFUOS9zMD:xNFAhdk1? MXm0PEBp M1;hXolv\HWlZYOgZZBweHSxc3nzJIF1KDFibl2= NFvwZ28zOzV|MkezNi=>
DpVp35 M2fQcGFxd3C2b4Ppd{BCe3OjeR?= MUmxM|ExNzFyMDDuUS=> M3SzblQ5KGh? Mo\UbY5lfWOnczDicJVvfCCjcH;weI9{cXN? MXeyN|U{Ojd|Mh?=
DpVp50 MWLBdI9xfG:|aYOgRZN{[Xl? NHG0TWUyNzFyL{GwNEBvVQ>? MVW0PEBp MknwbY5lfWOnczDicJVvfCCjcH;weI9{cXN? M33iOVI{PTN{N{Oy
DpP75  MlfTRZBweHSxc3nzJGF{e2G7 MWOxM|ExNzFyMDDuUS=> MYG0PEBp MYrpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? NYrzXHlKOjN3M{K3N|I>
SKOV-3 NED0eI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3noflHjiJN{MH7N MmDXO|IhcA>? MmjRSG1UVw>? NF\3eYtz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? MlXTNlMxOTB|NEi=
Brca1 WT MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7CO5ky6oDVMkDuUS=> M4fHfVczKGh? MUjEUXNQ NYfQUWxCemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NHf4d2MzOzBzMEO0PC=>
Brca1 Null MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPSNgKBmzJybl2= NX7BOZdqPzJiaB?= NUf1THQ4TE2VTx?= NX:1OXRpemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? Mli0NlMxOTB|NEi=
OVCAR-8  NWT5dGt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTWNgKBmzJybl2= MUe3NkBp M3OyXGROW09? MlrvdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NVzWXo5JOjNyMUCzOFg>
NCI/ADR-RES NUezcnJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDjNgKBmzJybl2= NET5e|M4OiCq MVHEUXNQ MmPndoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MYeyN|AyODN2OB?=
HCT116 M2mzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HaflUhdk1vNUCg{txO NH3QTHczPCCq M{jHVmROW09? MlPobY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NHfZNlUzOjl{NEm1PC=>
RKO MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInyXmc2KG6PLUWwJO69VQ>? M4e2VVI1KGh? MWDEUXNQ NIW4[3JqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MV6yNlkzPDl3OB?=
CO115 M1nNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe1JI5ONTVyIN88US=> M4\Kc|I1KGh? NInaNmVFVVOR MUPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MmmwNlI6OjR7NUi=
HFS NWrRZ2t2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO1JI5O NFu0W20zPC92OD:3NkBp MWnpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 MUWyNlExPjJ6Mh?=
LNCaP NX7RUod4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvMbnU2KG6P NWjUWIlEOjRxNEivO|IhcA>? M2fFPIlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> NUHkcGRbOjJzME[yPFI>
A549 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjMbI9DPSCwTR?= NXrLd2Z4OjRxNEivO|IhcA>? MVTpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 M1TpUlIzOTB4Mkiy
697  MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTDbHV[UUN3MPMAjV3jiIl{LkZCpI5O NUDBNVRmOjF3M{iyNVY>
697-R M3fYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDNTWM2OOLCiU5ihKk5NjcEoH7NxsA> NUTONFU2OjF3M{iyNVY>
HUT78 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy1R49MUUN3ME2xJI5O NWXXPFB2OjFzOUi1OFU>
THJ-16T NVPoepNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmP2NUBvVQ>? M{TBdFI1KGh? MVjpcohq[mm2czDj[YxtKGe{b4f0bC=> NEDTZ|QzODhzMEW2PC=>
HCT116 NInXVHpHfW6ldHnvckBCe3OjeR?= M2jCNVIxKG6P NGXDXFk5KGh? M4TPU41w\HWuYYTld{B1emGwc3PybZB1KGyndnXsd{Bnd3JiaIXu[JJm\HNib3[g[4Vv\XNiaX6g[Yl1cGW{IHTpdoVkfGmxbh?= MkLENlA4Ozl2NUS=
B104  MUHGeY5kfGmxbjDBd5NigQ>? NIHGd28zKG6P MnraNlQwPDhxN{KgbC=> M1\SXIlv[3KnYYPld{B1cGVic4Xy[oFk\SCneIDy[ZN{cW:wIH;mJGNFOjEEoB?= Mne2NlA3QDZ3MEW=
HL-60  MnniR5l1d3SxeHnjbZR6KEG|c3H5 NXjuNollOS13MECgcm0> MVeyOEBp M4DpS4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MVyyNFYzPDF4Mx?=
HP100 Mk\oR5l1d3SxeHnjbZR6KEG|c3H5 MUKxMVUxOCCwTR?= MXyyOEBp M{TZPYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NYHpS3U3OjB4MkSxOlM>
HL-60  M1q4OGZ2dmO2aX;uJGF{e2G7 NWDGZoNHOTBibl2= M{\tPVQwPi9zNjDo MnvFbY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq Mkm2NlA3OjRzNkO=
HP100 NYHiTHk4TnWwY4Tpc44hSXO|YYm= MlrxNVAhdk1? M{n4VlQwPi9zNjDo NV:5TWh5cW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo MoTVNlA3OjRzNkO=
HL-60  MoK2SpVv[3Srb36gRZN{[Xl? NYO0fId3OTBvNUCwJI5O MUe0JIg> MV;k[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB? MV:yNFYzPDF4Mx?=
HP100 NUO1THJGTnWwY4Tpc44hSXO|YYm= NXvtdGZTOTBvNUCwJI5O NGCxO3o1KGh? Moe1[IVkemWjc3XzJJRp\SCqaYP0c45mKGSnYXPleJlt[XOnIDjISGFEMSCjY4Tpeol1gcLi NXjlOodsOjB4MkSxOlM>
11z NEfKUXZMcW6jc3WgRZN{[Xl? M2q5dFMuOTByIH7N MkX6doVlfWOnczDISGFEKGWweontZZRq[yCjY4Tpeol1gSBqSVO1NOKhRSB4LkWgxtEhOC54IH7tc4wwVCl? M2HkXFIxPjB3MUS0
SKOV-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7wd|I1NzhxMU[gcm0> MX60PEBp M3;ITolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NF7XZ5IzODRyNEW2OC=>
OVCAR-3 NGq2b|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX2U5I1NzhxMU[gcm0> NXKxcplvPDhiaB?= MoHDbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MYqyNFQxPDV4NB?=
HBL-2 M4XiSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\qNk0yOCCwTR?= NUfTWm1NOjRiaB?= MoXpTWM2OD12LkOgcm0> MoLUNlAxPjhyOEC=
Jeko-1 NUDudopzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDnN2UzNTVyIH7N MlfpNlQhcA>? NUmzSWtlUUN3ME2xNUBvVQ>? NF;lXmczODB4OEC4NC=>
Granta-519 MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHTOU01OCCwTR?= MWCyOEBp NXj5Sld1UUN3ME21PE42KG6P NX\WN5lZOjByNkiwPFA>
L1236 MWLDfZRwfG:6aXPpeJkhSXO|YYm= MlXtNUBvVS1zMECg{txO NG\uW|g1QCCq NWXEdIZsTUN3ME2wMlA4KM7:TR?= MY[xPVI{OzR5MB?=
L428 M3WwdmN6fG:2b4jpZ4l1gSCDc4PhfS=> MkDRNUBvVS1zMECg{txO NVPVcmo1PDhiaB?= NIX6N4tGSzVyPUCuOFMh|ryP M1ftZlE6OjN|NEew
KM-H2 MnO1R5l1d3SxeHnjbZR6KEG|c3H5 NGLvXFUyKG6PLUGwNEDPxE1? NXTyfIpjPDhiaB?= NF71SY9GSzVyPUCuOVgh|ryP MlH6NVkzOzN2N{C=
L540Cy MlPuR5l1d3SxeHnjbZR6KEG|c3H5 NHK1NZgyKG6PLUGwNEDPxE1? M1zTO|Q5KGh? MmjQSWM2OD1yLkG2JO69VQ>? NIS2T5UyQTJ|M{S3NC=>
G401 NXfMPIxkTnWwY4Tpc44hSXO|YYm= MlfxNVAhdk1? MYKyOE81QC95MjDo MYDEUXNQ M2nrRolv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> M{HrTVE6OjJzNUi2
STM91-01 MlX6SpVv[3Srb36gRZN{[Xl? M1XzVVExKG6P NVvQXI41OjRxNEivO|IhcA>? MnyySG1UVw>? M1ryZ4lv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> MknLNVkzOjF3OE[=
SJSC  M3nF[mZ2dmO2aX;uJGF{e2G7 M3\UbFExKG6P MmrnNlQwPDhxN{KgbC=> NYXr[HJsTE2VTx?= NH3ucFdqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> MUmxPVIzOTV6Nh?=
BT16  NUTsRodRTnWwY4Tpc44hSXO|YYm= NVnUPG5[OTBibl2= M2TJZVI1NzR6L{eyJIg> NXLYWZZ1TE2VTx?= NF\SV3NqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> NWPEPFhsOTl{MkG1PFY>
NCI-H1299 MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVuwfHJPUUN3ME20MlbDuTBwMjDu[{9udA>? M4r0[FE6OTd7OEmw
NCI-2882 NE\5eYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLMTG5qUUN3ME2xMlbDuTBwMESgcocwdWx? NGW0SVYyQTF5OUi5NC=>
HCC95 NWfOfIVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjWTWM2OD1{LkZCtVAvODVibnevcYw> NIfPb3YyQTF5OUi5NC=>
NCI-H23 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KwTWlEPTB;Mj65xtExNjJibnevcYw> M{f5UlE6OTd7OEmw
NCI-H157 M2e3XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M161VGlEPTB;MT62xtExNjB{IH7nM41t NGfVZnUyQTF5OUi5NC=>
NCI-H460 MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33DeGlEPTB;Mj6xxtExNjB5IH7nM41t NUPlcpRPOTlzN{m4PVA>
NCI-H1975 M4HIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm0eZRKSzVyPUGuN:KyOC5yNDDu[{9udA>? M1fkflE6OTd7OEmw
NCI-H820 M3;UPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DpXGlEPTB;Mj60xtExNjFibnevcYw> M2jCPFE6OTd7OEmw
NCI-H1650 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7jTWM2OD12LkpCtVAvOyCwZz;tcC=> M3\IXlE6OTd7OEmw
DTC1 NH74fXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTBwNUGgcm0> NV\leXhkOTh3Nk[yOFY>
KAO M1zpR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3FT5VZUUN3ME2wMlkyKG6P NXXiT|hCOTh3Nk[yOFY>
SU-CCS-1 M4PPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPuXJFRUUN3ME2wMlg6KG6P NYnEXpJPOTh3Nk[yOFY>
SYO-1 NVHnVVVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwNkegcm0> M{DDeVE5PTZ4MkS2
FUJI MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXl[JZLUUN3ME2xMlMyKG6P M4S1bVE5PTZ4MkS2
SKNMC Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTFwMUegcm0> MVWxPFU3PjJ2Nh?=
402-91 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\XW3kyUUN3ME2xMlI3KG6P NX3FUIV7OTh3Nk[yOFY>
1765-92 NVHHbXZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFwN{egcm0> Ml[4NVg2PjZ{NE[=
JN-DSRCT-1 M3fWcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfqXIFuUUN3ME2xMlI2KG6P MW[xPFU3PjJ2Nh?=
NMS-2PC NV;kVlZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPrNnBKSzVyPUCuPFEhdk1? MUKxPFU3PjJ2Nh?=
HL60 MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3Wb29sUUN3ME2xMlg3KG6P NY\zUo42OTh3Nk[yOFY>
A549 M3LmNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLHTWM2OD1|LkK0JI5O NY\HZW1FOTh3Nk[yOFY>
SW480 MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJwNkmgcm0> MmW1NVg2PjZ{NE[=
MCF7 NV3tVINCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHGcIJTUUN3ME2zMlU2KG6P NX;yW|N6OTh3Nk[yOFY>
PC-3 M3Hp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF36TFNKSzVyPUKuOVEhdk1? NFLkNpMyQDV4NkK0Oi=>
MMRU NF7qXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJwNUegcm0> MnXFNVg2PjZ{NE[=
Hs68 M1HwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfXWZRKSzVyPU6xNEBvVQ>? M2LYN|E5PTZ4MkS2
hMSC-001F M2jpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRT5zMDDuUS=> M3XyXVE5PTZ4MkS2

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p21 / Cyclin D1; 

PubMed: 19682393     


NIH 3T3 cells stably expressing the indicated proteins were treated with DMSO (Vehicle) or the indicated concentration of romidepsin for 24 h. Cell lysates were analyzed by western blotting with antibodies to cyclin D1, p21 and β-actin (loading control). Data shown are representative of at least two independent experiments.

AcH3(K9) / Ac-α-Tubulin(K40) / Ac-NFκB2(K310) p65 / 3MeH3(K27); 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

HDAC3 / HDAC4 / HDAC6 / HDAC2; 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

γH2AX / PARP1 / Cleaved caspase3 / BAK / p21(waf1/cip1) / XIAP; 

PubMed: 26473529     


Western blot analysis of proteins involved in DNA-damage response and apoptosis. Established cell lines were exposed to different concentrations of romidepsin (Rom) for 48 h and total cell extracts were analyzed.

Cyclin E1 / BRCA1 / E2F1 / Cleaved PARP / H3Ac; 

PubMed: 27444036     


Western blot analysis of the effects of panobinostat (25 nM), vorinostat (5 µM) and romidepsin (10 nM) on expression of cyclin E1, E2F1, BRCA1, cleaved PARP and acetylated histone H3 in OVCAR-3 cells. Actin and histone H3 were loading controls. 

pAKT(S473) / pAKT(T308) / AKT; 

PubMed: 25492515     


Western blot analysis of phosphorylated AKT in PC3 cells. Cells were treated for 3 h with various concentrations of FK228. 

19682393 26473529 27444036 25492515
Growth inhibition assay
Cell viability; 

PubMed: 27444036     


Concentration-dependent effects of panobinostat and vorinostat in SRB viability assays in OVCAR-3 cells (72 h). Values are mean+SE of 3 independent experiments. 

27444036
Immunofluorescence
SS18/TLE1; 

PubMed: 27120803     


A significant decrease in detectable PLA signal following HDAC inhibition in SYO-1 cells.

Cleaved caspase-3; 

PubMed: 22531354     


TDP-B activates cleaved caspase-3 by immunofluorescence. Representative immunofluorescence staining for cleaved caspase 3 (green) in SKOV-3 ovarian cancer cells treated with 10 nM FK228, TDP-A or TDP-B after 24 h of exposure. The nuclei are stained with DAPI (blue).

27120803 22531354
体内研究 与PBS处理的对照组相比,单独使用Erlotinib 和 Romidepsin分别可以对NCI-H1299细胞系的异种移植生长抑制到72% 和 43% ,但是并不具有明显的统计学意义。只有当两种药物联用的时候才会对其生长造成明显的抑制作用,此时生长被抑制到28% [1]。在免疫功能低下的小鼠中,Romidepsin 会抑制皮下NB 异种移植的生长,这种抑制作用具有剂量依赖的特性 。此外, 在NB病人的肿瘤组织中Romidepsin 会诱导某些基因的表达,如 p21 和p75 以及NTRK (TrkA) [2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

- 合并

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
细胞实验:[3]
- 合并
  • Cell lines: NCI-H1975, NCI-H157, NCI-2882, NCI-H460 和 HCC95 细胞系
  • Concentrations: 1 ng/mL
  • Incubation Time: 72 小时
  • Method: 使用MTS法分析药物敏感性。在96孔平板中每孔接种2×103个细胞(包括NCI-H1975, NCI-H157, NCI-2882, NCI-H460和HCC95) 。24小时后, 在存在或者缺少1 ng/mL Romidepsin的条件下将细胞与不同浓度 (0.01 µM - 250 µM) 的Erlotinib 37°C 孵育72 小时。 MTS 溶液加到每个孔中37°C孵育1小时。利用分光光度计测量490 nm 处的光密度值。每种药物浓度的实验都设置8个复孔并重复两次。基于细胞生存曲线的吸光度值计算药物的半抑制浓度 (IC50) 。
    (Only for Reference)
动物实验:[5]
- 合并
  • Animal Models: 携带NCI-H1299 细胞的 BALB/c无胸腺裸小鼠
  • Dosages: 1.2 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 540.7
化学式

C24H36N4O6S2

CAS号 128517-07-7
储存条件 粉状
溶于溶剂
别名 FR 901228, NSC 630176

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03770000 Recruiting Drug: Tenalisib|Drug: Romidepsin T Cell Lymphoma Rhizen Pharmaceuticals SA March 12 2019 Phase 1|Phase 2
NCT02616965 Recruiting Drug: Romidepsin|Drug: Brentuximab vedotin Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics Inc.|Celgene Corporation February 22 2017 Phase 1
NCT02616874 Completed Drug: MVA.HIVconsv vaccine|Drug: Romidepsin HIV IrsiCaixa|Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA|Hospital Clinic of Barcelona|Hospital de Sant Pau|HIVACAT|University of Oxford|BCN Checkpoint February 2016 Phase 1
NCT03141203 Active not recruiting Drug: Romidepsin|Drug: Carfilzomib Peripheral T Cell Lymphoma University of Birmingham|Bloodwise|Celgene|Amgen July 13 2015 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

相关HDAC产品

Tags: 购买Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)供应商 | 采购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)价格 | Romidepsin (FK228, Depsipeptide)生产 | 订购Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID